112 related articles for article (PubMed ID: 3308483)
21. CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group.
Cameron DA; White JM; Proctor SJ; Prescott RJ; Leonard RC; Angus B; Cook MK; Dawes PJ; Dawson AA; Evans RG; Galloway MJ; Harris AL; Heppleston A; Horne CH; Krajewski AS; Lennard AL; Lessells AM; Lucraft HH; MacGillivray JB; Mackie MJ; Parker AC; Roberts JT; Taylor PR; Thompson WD
Eur J Cancer; 1997 Jul; 33(8):1195-201. PubMed ID: 9301442
[TBL] [Abstract][Full Text] [Related]
22. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Rhyne L; Spurr CL
Cancer; 1978 Nov; 42(5):2141-8. PubMed ID: 363253
[TBL] [Abstract][Full Text] [Related]
23. Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics. Cancer and Leukemia Group B.
Kiang DT; Kennedy BJ; Younger J; Perry MC; Schilling A; Korzun AH; Nowak BS; Wood W
Cancer; 1995 Feb; 75(3):826-30. PubMed ID: 7828133
[TBL] [Abstract][Full Text] [Related]
24. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
[TBL] [Abstract][Full Text] [Related]
26. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
[TBL] [Abstract][Full Text] [Related]
27. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.
Smalley RV; Lefante J; Bartolucci A; Carpenter J; Vogel C; Krauss S
Breast Cancer Res Treat; 1983; 3(2):209-20. PubMed ID: 6688538
[TBL] [Abstract][Full Text] [Related]
28. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
[TBL] [Abstract][Full Text] [Related]
31. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
Smith IE; Powles TJ
Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
[TBL] [Abstract][Full Text] [Related]
33. Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA).
Shipp SK; Muss HB; Westrick MA; Cooper MR; Jackson DV; Richards FC; White DR; Stuart JJ; Christian RM; Ramseur W
Cancer Chemother Pharmacol; 1983; 11(2):130-3. PubMed ID: 6354509
[TBL] [Abstract][Full Text] [Related]
34. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
J Clin Oncol; 1986 Feb; 4(2):186-93. PubMed ID: 2868074
[TBL] [Abstract][Full Text] [Related]
35. [A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer].
Inoue K; Ogawa M; Inagaki J; Horikoshi N; Ikeda K; Nakada H; Usui N; Adachi K; Tada A; Yamazaki H
Gan To Kagaku Ryoho; 1984 Sep; 11(9):1832-7. PubMed ID: 6433805
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial of two regimens of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone in advanced breast cancer.
Carmo-Pereira J; Costa FO; Henriques E; Carvalho V
Cancer Chemother Pharmacol; 1986; 17(1):87-90. PubMed ID: 3516431
[TBL] [Abstract][Full Text] [Related]
37. A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital.
Villalon AH; De Guzman LM; Samson MC; Guancia AA; Fernando GY; Romana IB
Oncology; 1997; 54 Suppl 1():2-6. PubMed ID: 8978577
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer.
Segaloff A; Hankey BF; Carter AC; Escher GC; Ansfield FJ; Talley RW
Breast Cancer Res Treat; 1985; 5(3):311-9. PubMed ID: 3896353
[TBL] [Abstract][Full Text] [Related]
40. [Metastatic breast cancer. Chemotherapy with adriamycin, vindesine, cyclophosphamide and 5 FU. Value of continuous 5 FU perfusion. Results of controlled trials].
Jouve M; Palangie T; Belli L; Dorval T; Garcia-Giralt E; Beuzeboc P; Scholl S; Mosseri V; Livartowski A; Vedrenne J
Bull Cancer; 1989; 76(6):643-52. PubMed ID: 2673438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
